MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- SANOFI INDIA LIMITED (pharmaceuticals)
- Latest 8 Quarter Result
Aventis Pharma Quarterly Results 
(HOCM)
Here are the latest quarterly results of Aventis Pharma. For more details, see the Aventis Pharma financial fact sheet and Aventis Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
Aventis Pharma Quarterly Results
| No. of Mths Qtr. Ending |
3
Mar-17 |
3
Jun-17 |
3
Sep-17 |
3
Dec-17 |
3
Mar-18 |
3
Jun-18 |
3
Sep-18 |
3
Dec-18 |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 5,529 | 6,006 | 6,675 | 6,704 | 6,177 | 6,836 | 7,438 | 7,264 | |
| Other income | Rs m | 159 | 284 | 208 | 182 | 226 | 208 | 262 | 201 | |
| Turnover | Rs m | 5,688 | 6,290 | 6,883 | 6,886 | 6,403 | 7,044 | 7,700 | 7,465 | |
| Expenses | Rs m | 4,514 | 4,852 | 4,838 | 5,360 | 4,833 | 5,191 | 5,565 | 5,891 | |
| Gross profit | Rs m | 1,015 | 1,154 | 1,837 | 1,344 | 1,344 | 1,645 | 1,873 | 1,373 | |
| Depreciation | Rs m | 253 | 255 | 257 | 257 | 254 | 254 | 260 | 259 | |
| Interest | Rs m | 4 | 0 | 0 | 11 | 0 | 0 | 0 | 7 | |
| Profit before tax | Rs m | 917 | 1,183 | 1,788 | 1,258 | 1,316 | 1,599 | 1,875 | 1,308 | |
| Tax | Rs m | 317 | 446 | 625 | 498 | 491 | 603 | 683 | 515 | |
| Profit after tax | Rs m | 600 | 737 | 1,163 | 760 | 825 | 996 | 1,192 | 793 | |
| Gross profit margin | % | 18.4 | 19.2 | 27.5 | 20.0 | 21.8 | 24.1 | 25.2 | 18.9 | |
| Effective tax rate | % | 34.6 | 37.7 | 35.0 | 39.6 | 37.3 | 37.7 | 36.4 | 39.4 | |
| Net profit margin | % | 10.9 | 12.3 | 17.4 | 11.3 | 13.4 | 14.6 | 16.0 | 10.9 | |
| Diluted EPS | Rs | 26.1 | 32.0 | 50.5 | 33.0 | 35.8 | 43.2 | 51.8 | 34.4 | |
| Diluted EPS (TTM) | Rs | 133.1 | 130.1 | 143.6 | 141.6 | 151.3 | 162.6 | 163.8 | 165.3 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: Aventis Pharma 3QFY19 Result Performance Review
More Pharmaceuticals Company Quarterly Results: WOCKHARDT STRIDES PHARMA SCIENCE MERCK AJANTA PHARMA SUN PHARMA
Compare SANOFI INDIA With: WOCKHARDT STRIDES PHARMA SCIENCE MERCK AJANTA PHARMA SUN PHARMA
Compare SANOFI INDIA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Get Ready for Record Highs(Podcast)
Globally, Traders were left scrambling after the Federal Reserve forecast zero interest-rate hikes this year and just one in 2020.
Views on news
SANOFI INDIA Announces Quarterly Results (3QFY19); Net Profit Up 4.3% (Quarterly Result Update)
Mar 5, 2019 | Updated on Mar 5, 2019For the quarter ended December 2018, SANOFI INDIA has posted a net profit of Rs 793 m (up 4.3% YoY). Sales on the other hand came in at Rs 7 bn (up 8.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)
Nov 6, 2018 | Updated on Nov 6, 2018For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsMost Popular
5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)
Mar 15, 20195 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.
Elections Don't Matter!(The Honest Truth)
Mar 13, 2019Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.
Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)
Mar 13, 2019The elements that fueled profit growth for these two companies led to a surge in their stock prices.
My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)
Mar 19, 2019The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.
This Small Cap Stock Could Offer Triple Digit Gains from its Current Price(Profit Hunter)
Mar 19, 2019If you are still waiting for signals, remember, there is no correct timing, only right time to Buy stocks. For select small caps, that time is now.
More|
| |
SANOFI INDIA SHARE PRICE
Mar 22, 2019 (Close)
TRACK SANOFI INDIA
- Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SANOFI INDIA
SANOFI INDIA 5-YR ANALYSIS
COMPARE SANOFI INDIA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.